Abstract: The present subject matter refers a blister-strip based dispenser (100) comprising a lever arm rotatable on receiving a user-actuation. A chassis (106, 108) is provided for supporting placement of at least one blister-strip (104) in the form of the coil. The blister-strip (104) comprises medicament-pockets at at-least one side of the blister-strip (104). A plurality of interconnected-rollers (110, 114, 116) comprises at-least one roller linked to the lever-arm and rotatable by the lever arm. The plurality of interconnected rollers (110, 114, 116) are configured for anchoring the blister-strip (104) from one end for enabling the placement in a coil-form and unwinding of the blister strip (104) from the coil-form, guiding at least two split-portions of the blister-strip (104), anchoring an end of each of said at-least two portions of the blister-strip (104) for winding the at-least two portions separately, and anchoring an end of a lid-foil peeled off the at least two portions for winding the lid-foil.

Abstract: A pharmaceutical composition for inhalation comprising R (+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients is described.

Abstract: Disclosed herein are methods of treating cancers by administration of a PAR-4 agonist.

Abstract: A pharmaceutical composition for inhalation comprising R (+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients is described.

Abstract: The present invention is concerned with the treatment of Pulmonary Arterial Hypertension (PAH) by administering Paliperidone. The instant invention further relates to use of a pharmaceutical composition comprising Paliperidone, for the treatment of PAH.

Abstract: A pharmaceutical long acting depot composition is provided as an aid to smoking cessation treatment. The formulation comprises a therapeutically effective amount of varenicline or its pharmaceutically acceptable derivative and pharmaceutically acceptable excipients. The process of preparation of the formulation is also provided.

Abstract: A pharmaceutical formulation is provided comprising combination of anti-tuberculosis drug drugs optionally in combination of bioenhancers. The formulation is used for the treatment of diseases caused by mycobacterium tuberculosis. The process of preparation of the formulation is also provided.

Abstract: A nasal spray assembly for administering a medicament to the nose of a user includes a nasal device and a container that has a reservoir containing the medicament. The reservoir is sealed by a movable piston. The nasal device includes a body, a cap that defines a socket into which the body can be inserted, an outlet, and a piercing element. The piercing element includes a piercer inlet and extends into the socket from a piercer stop within the socket. The nasal spray assembly is arranged such that, as the body is moved into the socket along a first axis, the piercing element pierces and passes through the piston such that the piercer inlet lies within the reservoir, contact between the piercer stop and piston forces the piston into the container, reducing the reservoir volume and forcing medicament from the reservoir through the conduit and out of the outlet.

Abstract: An adherence-monitoring and tracking device captures usage of a metered dose inhaler (MDI). The device includes an enclosure for enclosing a metered dose inhaler (MDI), and an electro-mechanical system forming a part of enclosure to sense and log the operation of the MDI. The electro-mechanical system includes at-least one transducer to capture one or more parameters pertaining to an operation of the MDI by the user. A microcontroller processes the captured parameters, and an output-unit renders data pertaining to operation of the MDI.

Abstract: Disclosed herein are improved formulations for the cabazitaxel. The formulations exhibit increased storage stability relative to other formulations, and are simpler for health care providers to prepare and administer to patients.

Abstract: The present invention relates to new polymorphs of dolutegravir sodium and processes for the preparation of the new polymorphs of dolutegravir sodium. The present invention also provides pharmaceutical compositions comprising these new polymorphs, and medical uses of the polymorphs.

Abstract: An oral or injectable pharmaceutical composition is provided for treating diseases caused by retroviruses or hepatitis B viruses. The composition comprises a therapeutically effective amount of at least one anti-retroviral drug and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof. Methods and kits are also provided.

Abstract: A pharmaceutical long acting depot composition is provided as an aid to smoking cessation treatment. The formulation comprises a therapeutically effective amount of varenicline or its pharmaceutically acceptable derivative and pharmaceutically acceptable excipients. The process of preparation of the formulation is also provided.

Abstract: The present invention discloses novel crystalline polymorphic forms of (9-[(R)-2-[[(S)-[[(S)-1-(isopropoxy carbonyl) ethyl] amino] phenoxyphosphinyl] methoxy]propyl] adenine hemifumarate and 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl] amino]phenoxy phosphinyl]methoxy]propyl] adenine monofumarate, methods of preparation, pharmaceutical compositions and methods of therapeutic treatment involving polymorphic forms thereof.

Abstract: Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of desipramine or a salt thereof. The compositions include an effective amount of desipramine or a salt thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.

Abstract: Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.

Abstract: The present invention relates to method of treatment of hepatitis C using hexestrol or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering hexestrol or a derivative thereof in combination with one or more anti-hepatitis C drugs.

Abstract: A pharmaceutical composition is provided for the treatment of B-cell proliferative disorders. The composition comprises a therapeutically effective amount of ibrutinib and a therapeutically effective amount of at least one alkaloid or derivative thereof. Methods and kits are also provided.

Abstract: Disclosed herein are methods of treating pulmonary hypertension, including pulmonary arterial hypertension, by administering to a patient in need thereof an effective amount of temozolomide, optionally in conjunction with one or more additional therapeutic agents. Compositions and kits including temozolomide for use in treating pulmonary hypertension, including pulmonary arterial hypertension, are also disclosed.

Abstract: Disclosed herein are methods for treating cancer in a subject in need thereof by administering an agent or pharmaceutically acceptable derivative thereof, optionally with another agent, induces prostate apoptosis response-4 (Par-4) production by non-cancerous normal cells, to promote apoptosis in cancer cells.